Trial Profile
DAPAMAAST: A Double-blind, Randomized, Phase IV, Mechanistic, Placebo-controlled, Cross-over, Single-center Study to Evaluate the Effects of 5 Weeks Dapagliflozin Treatment on Insulin Sensitivity in Skeletal Muscle in Type 2 Diabetes Mellitus Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2022
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms DAPAMAAST
- Sponsors AstraZeneca
- 23 Sep 2022 Results assessing the effects of 5 weeks of dapagliflozin treatment on skeletal muscle fat metabolism in type 2 diabetes patients, presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
- 15 Apr 2021 Results published in the Diabetes Care
- 25 Sep 2020 Results assessing effects of dapagliflozin (DAPA) on insulin sensitivity, 24h energy metabolism and skeletal muscle mitochondrial function in patients with type 2 diabetes, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes.